Cantuzumab ravtansine

Cantuzumab ravtansine
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
ATC code none
CAS Number 868747-45-9 N
ChemSpider none
 NYesY (what is this?)  (verify)

Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulphide linkage than Cantuzumab mertansine.[2]

See also


  1. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to ...
This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.